Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients

Roberta Gagliardini, Massimiliano Fabbiani, Manuela Colafigli, Alessandro D’Avino, Annalisa Mondi, Alberto Borghetti, Silvia Lamonica, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto

Research output: Contribution to journalArticle

Abstract

Tenofovir could have a direct lipid-lowering effect. The aim of our retrospective study was to investigate changes in cardiovascular risk after switching from a tenofovir-sparing to a tenofovir-containing backbone. Lipid parameters and cardiovascular risk [calculated using 10-years Framingham Risk Score (FRS) and 5-years DAD Risk Score (DRS)] were analysed at baseline and after three months. 273 patients were enrolled. After switching, significant decreases in total cholesterol (TC) (–8.2mg/dl, p < 0.001), LDL (–8.7mg/dl, p < 0.001) and DRS (mean –0.26%, p < 0.001) were observed, while a reduction in FRS was only observed in patients with pre-switch high TC or medium-high (>10%) FRS. Pre-switch factors associated with DRS reduction were higher TC, abacavir, new generation protease inhibitors, while zidovudine predicted an increase of DRS. Our results suggest that the improvement of lipid parameters observed after switching to a tenofovir-containing backbone could lead to a significant reduction in predicted cardiovascular risk, which became more evident in subjects with higher cardiovascular risk.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJournal of Chemotherapy
DOIs
Publication statusAccepted/In press - Dec 25 2016

Keywords

  • Cardiovascular risk
  • Cholesterol
  • DAD risk score
  • Dyslipidemia
  • Framingham risk score
  • HAART

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients'. Together they form a unique fingerprint.

  • Cite this

    Gagliardini, R., Fabbiani, M., Colafigli, M., D’Avino, A., Mondi, A., Borghetti, A., Lamonica, S., Cauda, R., Luca, A. D., & Giambenedetto, S. D. (Accepted/In press). Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. Journal of Chemotherapy, 1-9. https://doi.org/10.1080/1120009X.2016.1269040